published meta-analysis   sensitivity analysis   studies

azithromycin in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] 1.08[0.79; 1.47]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable deathsdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] 1.08[0.79; 1.47]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable deaths (time to event analysis only)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] 1.08[0.79; 1.47]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable clinical improvementdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] 0.74[0.51; 1.07]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable clinical improvement (14-day)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] 0.74[0.51; 1.07]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable clinical improvement (28-day)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04] 0.70[0.47; 1.04]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable clinical improvement (7-day)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40] 0.94[0.63; 1.40]COALITION II Covid-19 Brazil (Furtado), 202010%397NAnot evaluable related SAE (TRSAE)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11] 1.24[0.50; 3.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable serious adverse eventsdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77] 1.20[0.82; 1.77]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable long QTdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43] 0.90[0.56; 1.43]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable renal impairmentdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11] 1.44[0.99; 2.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-19 09:02 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 619 - roots T: 290